Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pyruvate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.91 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyruvate SCHEMBL148220 | 0.95 | — | — | |
| Pyruvate SCHEMBL6743471 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL597752 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL598199 | 0.91 | — | — | |
| Pyruvate SCHEMBL3745552 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL7936306 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL18226 | 0.91 | — | — | |
| Pyruvate SCHEMBL1332703 | 0.91 | — | — | |
| Pyruvate SCHEMBL1332958 | 0.91 | — | — | |
| Pyruvate SCHEMBL6743473 | 0.91 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636311-B2 | Topically administered strontium-containing complexes for treating pain, pruritis and inflammation | GALLEON LABS LLC (US) | 2026-05-26 | — | — | US | claimed |
| US-20250099498-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | GALLEON LABS LLC (US) | 2025-03-27 | — | — | US | claimed |
| US-12121536-B2 | Strontium based compositions and formulations for pain, pruritus, and inflammation | GALLEON LABS LLC (US) | 2024-10-22 | — | — | US | claimed |
| US-20240041919-A1 | TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION | GALLEON LABS LLC | 2024-02-08 | — | — | US | claimed |
| US-11801261-B2 | Topically administered strontium-containing complexes for treating pain, pruritis and inflammation | GALLEON LABS LLC (US) | 2023-10-31 | — | — | US | claimed |
| CN-115414265-A | Composition and face cream with effects of color correction, skin tendering and moisturizing and preparation method thereof | 中国科学院过程工程研究所 | 2022-12-02 | — | — | CN | claimed |
| US-20220323485-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | PIKE, JOSEPH D. | 2022-10-13 | — | — | US | claimed |
| EP-2827847-B1 | TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION | GALLEON LABS LLC (US) | 2022-09-14 | — | — | EP | claimed |
| EP-3284462-B1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | GALLEON LABS LLC (US) | 2022-08-03 | — | — | EP | claimed |
| US-20220054535-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | STRONTIUM NEUROGENICS INC (US) | 2022-02-24 | — | — | US | claimed |
| EP-1622630-A2 | STRONTIUM COMBINATIONS FOR THE PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS | Osteologix A/S (DK) | 2006-02-08 | — | — | EP | claimed |
| WO-2005123193-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123130-A2 | IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123192-A2 | IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123098-A2 | PREVENTING GASTROINTESTINAL SIDE-EFFECTS WITH STRONTIUM SALTS | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005108339-A2 | HIGH YIELD AND RAPID SYNTHESES METHODS FOR PRODUCING METALLO-ORGANIC SALTS | OSTEOLOGIX A/S (DK) | 2005-11-17 | — | — | WO | claimed |
| WO-2005082385-A1 | STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS | OSTEOLOGIX A/S (DK) | 2005-09-09 | — | — | WO | claimed |
| EP-1534305-A2 | TREATING CARTILAGE / BONE CONDITIONS WITH WATER-SOLUBLE STRONTIUM SALTS | Osteologix A/S (DK) | 2005-06-01 | — | — | EP | claimed |
| WO-2004098619-A2 | TREATING CARTILAGE / BONE CONDITIONS WITH WATER-SOLUBLE STRONTIUM SALTS | OSTEOLOGIX A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| WO-2004098618-A2 | STRONTIUM COMBINATIONS FOR PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS | OSTEOLOGIX A/S (DK) | 2004-11-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636311-B2 | Topically administered strontium-containing complexes for treating pain, pruritis and inflammation | SUCNR1, TRPV1, TRPV2 | CA4 559/4885CA1 208/4885TSHR 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.